ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Exicure, Inc. (XCUR) stock surged +24.88%, trading at $13.20 on NASDAQ, up from the previous close of $10.57. The stock opened at $12.69, fluctuating between $12.30 and $13.53 in the recent session.
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Employees | 6 |
Beta | 3.85 |
Sales or Revenue | $28.83M |
5Y Sales Change% | -1% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |